GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hikma Pharmaceuticals HIK.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1,686.00p

-0.06%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Hikma Pharmaceuticals — daily HIK

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Hikma Pharmaceuticals on TradingView ↗
Market value
£3.77bn
Last close × shares
Volume
401.5k
Shares, 20 Nov 2026
Price to earnings
13.0
Dividend yield
3.19%

About Hikma Pharmaceuticals

Its shares trade on LSE under the ticker HIK.L. It has been listed since 1 November 2005. In the fiscal year to 31 December 2025, it reported revenue of $3.35bn and net income of $410.4m. At that date it held total assets of $5.67bn and shareholders' equity of $2.59bn.

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The firm's segments include Branded, Injectables, Generics and Others. The company sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The firm sells specialized generic injectable products across the globe. The company also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The firm's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Figures and description from our data supplier, not checked against the company's own report.

More about Hikma Pharmaceuticals →

Latest on Hikma Pharmaceuticals

Our reporting

Next results

25 Feb 2027

Due on 25 Feb 2027. Analysts expect earnings of 0.86 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Hikma Pharmaceuticals's ticker?

Hikma Pharmaceuticals trades as HIK.L on LSE, under ISIN GB00B0LCW083.

What was Hikma Pharmaceuticals's last closing price?

1,686.00p on 20 Nov 2026. The figure is in GBp and is never converted.

When does Hikma Pharmaceuticals next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.